Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...
The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint ...
DUBLIN 18, Ireland (AP) — Icon PLC (ICLR) on Wednesday reported fourth-quarter net income of $260 million. The Dublin 18, Ireland-based company said it had profit of $3.16 per share. Earnings, ...
Highlights Net business wins in the quarter of $2,413 million; a net book to bill in the quarter of 1.18. Full year net business wins of $9,974 million; a net book to bill of 1.20. Closing ...
22h
Hosted on MSNIcon PLC (ICLR) Q4 Earnings and Revenues Top EstimatesIcon PLC (ICLR) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $3.46 per share a year ago. These figures are ...
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...
Icon plc has launched a new buyback program to repurchase up to $750 million of its shares. The total value of the authorized share repurchase is now up to $1 billion, the healthcare intelligence and ...
For the full year 2024, ICON reported revenue of $8.28 billion, a 2% increase YoY. Adjusted diluted EPS rose 9.5% to $14.00. Looking ahead, the company reaffirmed its 2025 financial guidance, ...
Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and October 23, 2024. ICON is a ...
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ICON plc (NASDAQ: ICLR) and certain of its senior ...
The market expects Icon PLC (ICLR) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results